BL 8040

Drug Profile

BL 8040

Alternative Names: 4F-Benzoyl-TN14003; BKT-140; BL-8040; TN-14003

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Kyoto University
  • Developer Biokine Therapeutics; BioLineRx; Merck AG; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Peptides
  • Mechanism of Action Apoptosis stimulants; Cell movement activators; CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Stem cell mobilisation
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Pancreatic cancer; Stem cell mobilisation
  • Phase I/II Aplastic anaemia; Multiple myeloma; Myelodysplastic syndromes
  • Preclinical Autoimmune disorders; Chronic myeloid leukaemia; Thrombocytopenia

Most Recent Events

  • 17 Jan 2017 BioLineRx initiates enrolment in second phase IIa trial for Pancreatic cancer (Combination therapy, Metastatic disease) in USA
  • 01 Dec 2016 BioLineRx initiates enrolment in a phase II trial for Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (NCT02907099)
  • 03 Nov 2016 Updated efficacy and adverse events data from a phase IIa trial in Acute myeloid leukaemia presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exhibition (ASH 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top